Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK594285PMID: 37603672
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 901119-35-5
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of fostamatinib during breastfeeding. Because the active metabolite of fostamatinib (R406) is 98.3% bound to plasma proteins, the amount in milk is likely to be low. However, the active metabolites has a half-life of 15 hours, and might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during fostamatinib therapy and for at least 1 month after the final dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Fostamatinib
CAS Registry Number
901119-35-5
Drug Class
Breast Feeding
Milk, Human
Enzyme Inhibitors
Protein Kinase Inhibitors
Signal Transduction Inhibitors
Tyrosine Kinase Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation.[Drug Metab Dispos. 2010]Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation.Sweeny DJ, Li W, Clough J, Bhamidipati S, Singh R, Park G, Baluom M, Grossbard E, Lau DT. Drug Metab Dispos. 2010 Jul; 38(7):1166-76. Epub 2010 Apr 6.
- Review Trametinib.[Drugs and Lactation Database (...]Review Trametinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Sunitinib.[Drugs and Lactation Database (...]Review Sunitinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Pazopanib.[Drugs and Lactation Database (...]Review Pazopanib.. Drugs and Lactation Database (LactMed®). 2006
- Review Osimertinib.[Drugs and Lactation Database (...]Review Osimertinib.. Drugs and Lactation Database (LactMed®). 2006
- Fostamatinib - Drugs and Lactation Database (LactMed®)Fostamatinib - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...